RxDoctor Payments Data

Steven Suh, MD

Ophthalmology · Westerville, OHNPI 1023011475

Payments from drug & device makers

$5,334in general payments, 2019–2025

Across 144 payments — averaging $37.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Microsurgical Technology, Inc.$3K
  • Tarsus Pharmaceuticals, Inc.$444
  • Alcon$329
  • AbbVie$300
  • Sun Pharmaceutical Industries Inc.$282
  • Oyster Point Pharma, Inc.$251
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,76452%
  • Gifts$190%
  • Charitable contribution$2,55048%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,334 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$339,170
Medicare patients
1,074
Services billed
2,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine26$42,263
VyzultaLatanoprostene Bunod24$13,980
LumiganBimatoprost29$11,578
Latanoprost1,112$10,693
Brimonidine Tartrate112$9,029
RocklatanNetarsudil Mesylat/Latanoprost14$7,715
RhopressaNetarsudil Mesylate12$7,375
CombiganBrimonidine Tartrate/Timolol14$5,216
Timolol Maleate386$3,925
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol37$3,258
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat185$3,183
Prednisolone Acetate59$2,705
Fluorometholone47$2,610
Dorzolamide Hcl88$1,410
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha39$288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$300$59,05669 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$30$15,09026 claims
Bausch & Lomb Americas Inc.Vyzulta$237$13,98024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Westerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →